Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

Rhea-AI Summary

Athenex (NASDAQ: ATNX), a biopharmaceutical firm focused on cancer therapies, will report its second quarter 2022 financial and corporate updates on July 28, 2022, before market opening. The management team will host a conference call at 8:00 a.m. ET. Interested participants can join by dialing the domestic number (855) 327-6837 or the international number (631) 891-4304, using the passcode 10019801. Further details and a live audio webcast will be available on Athenex's Investor Relations website.

Positive

• Scheduled second quarter 2022 corporate and financial update on July 28, 2022.
• Management hosting a conference call allows direct engagement with investors.

Negative

• None.

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic: (855) 327-6837

International: (631) 891-4304

Passcode: 10019801

The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible and tolerable treatments. For more information, please visit www.athenex.com.

Athenex Contacts

Investor Relations

Daniel Lang, MD
Athenex, Inc.
E-mail: danlang@athenex.com

Caileigh Dougherty
Athenex, Inc.
E-mail: cdougherty@athenex.com

FAQ

When will Athenex provide its Q2 2022 financial update?

Athenex will provide its Q2 2022 financial update on July 28, 2022.

What time is the Athenex conference call for Q2 2022 results?

The conference call for Athenex's Q2 2022 results is scheduled for 8:00 a.m. ET.

How can I participate in the Athenex Q2 2022 conference call?

To participate in the call, dial (855) 327-6837 for domestic or (631) 891-4304 for international calls, with passcode 10019801.

Where can I find the webcast for Athenex's financial update?

The webcast for Athenex's financial update can be accessed on the Investor Relations section of their website.